<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>TB R&#38;D Matters Blog &#187; nih/niaid</title>
	<atom:link href="http://www.newtbdrugs.org/blog/tag/nihniaid/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.newtbdrugs.org/blog</link>
	<description>Working Towards a Faster Cure for Tuberculosis</description>
	<lastBuildDate>Sat, 19 May 2012 12:57:01 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>World TB Day Coverage: New Combo TB Drug Trial Announced</title>
		<link>http://www.newtbdrugs.org/blog/world-tb-day-coverage-new-combo-tb-drug-trial-announced/</link>
		<comments>http://www.newtbdrugs.org/blog/world-tb-day-coverage-new-combo-tb-drug-trial-announced/#comments</comments>
		<pubDate>Wed, 21 Mar 2012 17:12:21 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Announcements]]></category>
		<category><![CDATA[Events]]></category>
		<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[cptr]]></category>
		<category><![CDATA[diagnostics]]></category>
		<category><![CDATA[fda]]></category>
		<category><![CDATA[mdr]]></category>
		<category><![CDATA[nih/niaid]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[tb alliance]]></category>
		<category><![CDATA[usaid]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3571</guid>
		<description><![CDATA[During the "Cure All: A briefing on the status of the most promising new TB drugs research" sponsored by the Critical Path to New TB Drug Regimens (CPTR) on Monday, March 19, Dr. Mel Spigelman, CEO &#038; President, of TB Alliance announced the launch of the NC002 trial, a combination drug trial that establishes a new pathway to TB and multi-drug resistant TB treatment. The meeting also involved high-level officials from U.S. agencies that support TB research including Anthony Fauci (Director, NIAID/NIH), Janet Woodcock (Director, CDER/FDA), and Robert Clay (Deputy Assistant Administrator, Global Health Bureau/USAID). ]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/world-tb-day-coverage-new-combo-tb-drug-trial-announced/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Summary Available!  TB Clinical Trials Consultants Meeting</title>
		<link>http://www.newtbdrugs.org/blog/summary-available-tb-clinical-trials-consultants-meeting/</link>
		<comments>http://www.newtbdrugs.org/blog/summary-available-tb-clinical-trials-consultants-meeting/#comments</comments>
		<pubDate>Fri, 27 Jan 2012 21:20:21 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Announcements]]></category>
		<category><![CDATA[Events]]></category>
		<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[cdc]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[cptr]]></category>
		<category><![CDATA[endpoints]]></category>
		<category><![CDATA[intertb]]></category>
		<category><![CDATA[london]]></category>
		<category><![CDATA[nih/niaid]]></category>
		<category><![CDATA[phase 2]]></category>
		<category><![CDATA[phase 3]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[tb alliance]]></category>
		<category><![CDATA[united kingdom]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3444</guid>
		<description><![CDATA[On November 17 and 18, a TB Clinical Trials Consultants Meeting was held at St. George's, University of London.  The meeting was organized by CDC, CPTR, INTERTB, NIH, and TB Alliance.  The meeting was convened to catalog expert opinion on the conduct of Phase 2 and Phase 3 clinical trials in tuberculosis. ]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/summary-available-tb-clinical-trials-consultants-meeting/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  Podcast interview with Dr. Gyanu Lamicchane</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-dr-gyanu-lamicchane/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-dr-gyanu-lamicchane/#comments</comments>
		<pubDate>Tue, 08 Nov 2011 21:47:25 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[WGND Podcast Series]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[JHU]]></category>
		<category><![CDATA[nih/niaid]]></category>
		<category><![CDATA[podcast]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[targets]]></category>
		<category><![CDATA[voices]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3325</guid>
		<description><![CDATA[Microbial geneticist Dr.  Gyanu Lamichhane of the Johns Hopkins Center for Tuberculosis Research is one of 49 recipients of the New Innovator Award, which is given to promising scientists in the early stages of their careers and is supported directly with $1.5 million in research funding over five years.  In this interview, we discuss the award and the related research that lead to the award, as well as, Dr. Lamichhane's motivation to work with TB.  Additional links to TB R&#038;D news are included.  ]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-dr-gyanu-lamicchane/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  Zinc Used by Host to Fight TB</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-zinc-used-by-host-to-fight-tb/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-zinc-used-by-host-to-fight-tb/#comments</comments>
		<pubDate>Tue, 20 Sep 2011 18:47:17 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[Life Cycle of Tuberculosis]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[france]]></category>
		<category><![CDATA[Johns Hopkins]]></category>
		<category><![CDATA[networks]]></category>
		<category><![CDATA[nih/niaid]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[targets]]></category>
		<category><![CDATA[tb alliance]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3205</guid>
		<description><![CDATA[This week, we provide an brief overview of research supported by CNRS, INSERM, Institut Pasteur and other donors providing new evidence of the role of Zinc in the body's immune response to intracellular infection by M.tb. and the microbe's strategy to subvert this defense. Additional links to TB R&#038;D news are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-zinc-used-by-host-to-fight-tb/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>USAID Head: TB Drug Research Critical in Turning Tide Against Epidemic</title>
		<link>http://www.newtbdrugs.org/blog/usaid-head-tb-drug-research-critical-in-turning-tide-against-epidemic/</link>
		<comments>http://www.newtbdrugs.org/blog/usaid-head-tb-drug-research-critical-in-turning-tide-against-epidemic/#comments</comments>
		<pubDate>Thu, 17 Feb 2011 16:10:03 +0000</pubDate>
		<dc:creator>Derek Ambrosino</dc:creator>
				<category><![CDATA[Events]]></category>
		<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[Video]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[nih/niaid]]></category>
		<category><![CDATA[press]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=2177</guid>
		<description><![CDATA[Dr. Rajiv Shah, Administrator of the United States Agency for International Development (USAID) presented the most recent David E. Barmes Global Health Lecture on Tuesday, February 15, 2011 on the NIH Campus in Bethesda, Maryland. ]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/usaid-head-tb-drug-research-critical-in-turning-tide-against-epidemic/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>WGND 2010 Annual Meeting: Panel Discussion</title>
		<link>http://www.newtbdrugs.org/blog/wgnd-2010-annual-meeting-panel-discussion/</link>
		<comments>http://www.newtbdrugs.org/blog/wgnd-2010-annual-meeting-panel-discussion/#comments</comments>
		<pubDate>Tue, 23 Nov 2010 14:17:56 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Events]]></category>
		<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[nih/niaid]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[tb alliance]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=1773</guid>
		<description><![CDATA[Following the guest speakers, several representatives from companies conducting clinical trials of TB drug candidates presented brief updates on progress made in the clinical development of their candidates. We recap the presentations here and offer .pdf downloads of the original presentations.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/wgnd-2010-annual-meeting-panel-discussion/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
		</item>
		<item>
		<title>WGND 2010 Annual Meeting Recap</title>
		<link>http://www.newtbdrugs.org/blog/wgnd-2010-annual-meeting-recap/</link>
		<comments>http://www.newtbdrugs.org/blog/wgnd-2010-annual-meeting-recap/#comments</comments>
		<pubDate>Tue, 23 Nov 2010 14:15:35 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Events]]></category>
		<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[nih/niaid]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[tb alliance]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=1761</guid>
		<description><![CDATA[Thank you to everyone who was able to join us in Berlin. This recap summarizes the work that was presented at our Annual Meeting on November 12. Co-chairs of WGND, Mel Spigelmen and Bill Bishai opened the annual meeting by welcoming the attendees and briefly reviewing the agenda for the meeting.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/wgnd-2010-annual-meeting-recap/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
		</item>
		<item>
		<title>Report from NIH/NIAID Town Hall on HIV/AIDS Clinical Trial Network Restructuring</title>
		<link>http://www.newtbdrugs.org/blog/report-from-nihniaid-town-hall-on-hivaids-clinical-trial-network-restructuring/</link>
		<comments>http://www.newtbdrugs.org/blog/report-from-nihniaid-town-hall-on-hivaids-clinical-trial-network-restructuring/#comments</comments>
		<pubDate>Wed, 27 Oct 2010 01:12:08 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Events]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[hiv/aids]]></category>
		<category><![CDATA[nih/niaid]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=1670</guid>
		<description><![CDATA[Lisan Parker was on hand at the Town Hall Meeting to Examine the Restructuring of the NIH/NIAID Clinical Trials Networks for HIV/AIDS &#038; Other Infectious Diseases and filed this report.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/report-from-nihniaid-town-hall-on-hivaids-clinical-trial-network-restructuring/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An Interview with Barbara Laughon of NIH/NIAID</title>
		<link>http://www.newtbdrugs.org/blog/an-interview-with-barbara-laughon-of-nihniaid/</link>
		<comments>http://www.newtbdrugs.org/blog/an-interview-with-barbara-laughon-of-nihniaid/#comments</comments>
		<pubDate>Thu, 11 Mar 2010 13:00:34 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Video]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[nih/niaid]]></category>
		<category><![CDATA[voices]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=359</guid>
		<description><![CDATA[Dr. Barbara Laughon works in the Office of the Director, Division of Microbiology and Infectious Diseases at the National Institute of Allergy &#38; Infectious Diseases (NIH/NIAID). She is also a Core Group member of the Working Group on New TB Drugs and is the Candidates Subgroup leader. This interview was filmed at JHU on November [...]]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/an-interview-with-barbara-laughon-of-nihniaid/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

